Table 3.
Univariate and multivariate logistic regression models for minimal symptom expression in the development group
| Variables | Subgroups | Univariate analysis | Multivariate analysis** | ||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Gender | Male | 1 | |||||
| Female | 0.5 | 0.19–1.25 | 0.146 | ||||
| Age at onset | EOMG | 1 | |||||
| LOMG | 1.2 | 0.42–3.73 | 0.744 | ||||
| Elderly-onset MG | 0.76 | 0.18–3.90 | 0.713 | ||||
| MGFA classification | II | 1 | |||||
| III | 1.19 | 0.44–3.45 | 0.741 | ||||
| IV | 0.57 | 0.09–4.58 | 0.553 | ||||
| Thymoma | Yes | 1 | |||||
| No | 0.71 | 0.25–1.86 | 0.494 | ||||
| Thymectomy | No | 1 | |||||
| Yes | 2.2 | 0.73–8.23 | 0.192 | ||||
| Worsening | Yes | ||||||
| No | 2.36 | 0.78–8.80 | 0.155 | ||||
| Autoimmune disease | No | 1 | |||||
| Yes | 0.85 | 0.22–4.21 | 0.827 | ||||
| MMT score | > 26 | 1 | |||||
| ≤ 26 | 2.36 | 0.54–9.72 | 0.229 | ||||
| Anti-AChR Abs titer, nmol/L | > 9 | 1 | |||||
| ≤ 9 | 0.49 | 0.15–1.37 | 0.197 | ||||
| Duration, months | > 12 | 1 | 1 | ||||
| ≤ 12 | 4.41 | 1.73–11.90 | 0.002** | 3.45 | 1.23–10.24 | 0.021 | |
| Pyridostigmine dosage, mg/day | ≤ 240 | ||||||
| > 240 | 0.46 | 0.10–2.50 | 0.339 | ||||
| MG-ADL score | > 3 | 1 | |||||
| ≤ 3 | 2.74 | 0.69–18.36 | 0.207 | ||||
| Bulbar score | ≤ 1 | 1 | |||||
| > 1 | 2.01 | 0.81–5.19 | 0.136 | ||||
| Respiratory function | Normal | 1 | |||||
| Abnormal | 1.53 | 0.56–4.65 | 0.426 | ||||
| Limb score | ≤ 1 | 1 | |||||
| > 1 | 1.51 | 0.57–4.31 | 0.418 | ||||
| Ocular score | > 2 | 1 | |||||
| ≤ 2 | 2.87 | 1.11–8.15 | 0.036** | 6.00 | 1.82–24.58 | 0.006 | |
| QMG score | ≤ 13 | 1 | 1 | ||||
| > 13 | 2.36 | 0.78–8.80 | 0.155 | 11.95 | 2.31–95.82 | 0.008 | |
| Extraocular muscle score | ≥ 1 | 1 | |||||
| 0 | 2.52 | 0.84–9.39 | 0.124 | ||||
| Bulbar muscle score | ≥ 1 | 1 | |||||
| 0 | 0.51 | 0.17–1.37 | 0.198 | ||||
| Respiratory muscle score | ≥ 80 | 1 | |||||
| 65–79 | 0.98 | 0.36–2.79 | |||||
| 50–64 | 0.75 | 0.28–9.48 | |||||
| < 50 | 0.81 | 0.07–16.83 | |||||
| Gross motor score | > 9 | 1 | 1 | ||||
| ≤ 9 | 2.67 | 0.90–7.81 | 0.072* | 10.82 | 2.22–69.13 | 0.006 | |
| Axial motor score | > 2 | 1 | |||||
| ≤ 2 | 1.70 | 0.33–7.48 | 0.493 | ||||
CI, confidence interval, OR odds ratio, MSE minimal symptom expression, EOMG early-onset myasthenia gravis, LOMG late-onset myasthenia gravis, MG myasthenia gravis, MGFA Myasthenia Gravis Foundation of America, AChR acetylcholine receptor, Abs antibodies, MMT manual muscle test, MG-ADL myasthenia gravis-activity of daily living, QMG quantitative myasthenia gravis
*Statistical significance (α = 0.1)
**Statistical significance (α = 0.05)